Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2025)

Contineum Therapeutics has reported Retained Earnings over the past 3 years, most recently at $265000.0 for Q3 2025.

  • Quarterly results put Retained Earnings at $265000.0 for Q3 2025, up 100.26% from a year ago — trailing twelve months through Sep 2025 was $265000.0 (up 100.26% YoY), and the annual figure for FY2024 was -$117.4 million, down 108805.56%.
  • Retained Earnings for Q3 2025 was $265000.0 at Contineum Therapeutics, up from -$149.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for CTNM hit a ceiling of $265000.0 in Q3 2025 and a floor of -$149.4 million in Q2 2025.
  • Median Retained Earnings over the past 3 years was -$51.5 million (2024), compared with a mean of -$62.9 million.
  • Peak annual rise in Retained Earnings hit 100.26% in 2025, while the deepest fall reached 229900.0% in 2025.
  • Contineum Therapeutics' Retained Earnings stood at $108000.0 in 2023, then crashed by 108805.56% to -$117.4 million in 2024, then surged by 100.23% to $265000.0 in 2025.
  • The last three reported values for Retained Earnings were $265000.0 (Q3 2025), -$149.4 million (Q2 2025), and -$133.4 million (Q1 2025) per Business Quant data.